JAK2 and acute lymphoblastic leukemia: In clinical trials, the dual JAK2/3 inhibitor AG-490 significantly prevents B-cell growth in overcontrol in patients with acute lymphoblastic leukemia by preventing the inconsistent constitutive activation of JAK2 [6].